- Home
- DOW vs BIIB Comparison
DOW vs BIIB Comparison
Compare DOW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOW
- BIIB
- Stock Information
- Founded
- DOW 1897
- BIIB 1978
- Country
- DOW United States
- BIIB United States
- Employees
- DOW N/A
- BIIB N/A
- Industry
- DOW Major Chemicals
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- DOW Industrials
- BIIB Health Care
- Exchange
- DOW Nasdaq
- BIIB Nasdaq
- Market Cap
- DOW 17.4B
- BIIB 18.7B
- IPO Year
- DOW N/A
- BIIB 1991
- Fundamental
- Price
- DOW $24.09
- BIIB $143.81
- Analyst Decision
- DOW Hold
- BIIB Buy
- Analyst Count
- DOW 15
- BIIB 26
- Target Price
- DOW $28.40
- BIIB $183.36
- AVG Volume (30 Days)
- DOW 13.1M
- BIIB 1.5M
- Earning Date
- DOW 10-23-2025
- BIIB 10-29-2025
- Dividend Yield
- DOW 5.81%
- BIIB N/A
- EPS Growth
- DOW N/A
- BIIB 31.67
- EPS
- DOW N/A
- BIIB 10.45
- Revenue
- DOW $41,819,000,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- DOW N/A
- BIIB $2.00
- Revenue Next Year
- DOW $2.80
- BIIB N/A
- P/E Ratio
- DOW N/A
- BIIB $13.76
- Revenue Growth
- DOW N/A
- BIIB 3.36
- 52 Week Low
- DOW $20.40
- BIIB $110.04
- 52 Week High
- DOW $55.67
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- DOW 47.58
- BIIB 57.91
- Support Level
- DOW $24.05
- BIIB $141.12
- Resistance Level
- DOW $25.77
- BIIB $147.23
- Average True Range (ATR)
- DOW 0.96
- BIIB 4.56
- MACD
- DOW 0.05
- BIIB 0.08
- Stochastic Oscillator
- DOW 36.60
- BIIB 65.51
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.